



October 28, 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi.

UNDER SEALED COVER

Subject: **Financial Results for the quarter ended September 30, 2026**

Dear Sir,

We have to inform you that the Board of Directors in their Meeting held on today, October 28, 2026 recommended the following:

(i) **Cash Dividend (Interim)**

Nil

(ii) **Bonus Shares**

Nil

(iii) **Right Shares**

Nil

(iv) **Any other Entitlement / Corporate Action**

N/A

(v) **Any other price-sensitive information**

A self-explanatory letter containing material and price-sensitive information is attached herewith as Pages 2–3 for information of the Exchange. You are requested to kindly disseminate the information to the TRE Certificate Holders of the Exchange accordingly.

The quarterly financial results of the Company are enclosed herewith as page no. 4 – 8.

The Quarterly Accounts of the Company will be transmitted through PUCARS to the Exchange within 30 days of the close of the Quarter. These accounts can also be viewed at our website www.otsuka.pk.

Yours faithfully,
For and on behalf of Otsuka Pakistan Limited


Chief Executive Officer

Encl.: As mentioned above

Otsuka Pakistan Ltd.

Head Office : 30-B, Sindhi Muslim Co-operative Housing Society, Karachi-74400, Pakistan. Phones : (+9221) 3452 8651-54 URL www.otsuka.pk
Factory : No. F/4-9, Hub Industrial Trading Estate, Distt. Lasbella, Balochistan, Pakistan. Phones: (+92853) 302363, 303218, 303517, 304395-97



October 28, 2026

The General Manager
Pakistan Stock Exchange
Stock Exchange Building
Stock Exchange Road
Karachi – 74000.

Subject: Disclosure of Material Information

Dear Sir,

In accordance with Sections 96 and 131 of the Securities Act, 2015 as well as Clause 5.6.1(a) of the Rule Book of Pakistan Stock Exchange Limited and other applicable laws and regulations, we hereby convey the following material information:

The Board of Directors of the Company in its meeting held on October 28, 2026 has approved the reorganizing/ restructuring of its manufacturing facilities located at F/4-9, Hub Industrial Trading Estate, Hub, Lasbella, Balochistan, whereunder the manufacturing of the 1,000 ml products as set out in **Table 1** below, is planned to be transferred from Production Line-II to Production Line-I with effect from January 1, 2027 and the filling machinery installed on Production Line-II, having a carrying amount of approximately Rs. 81 million as at the reporting date, is expected to remain idle as Line-II will be closed following the transfer of production.

Table 1

S. No	Registration No	Drug Name	Generic Substances/ formulation	Pack Size
1	007782	Ringolact	Lactated Ringer's Inj. USP	1000 mL
2	011224	Ringolact-D	5% Dextrose and Lactated Ringer's Inj. USP	1000 mL
3	011225	Plabolyte-M	5% Dextrose and Electrolytes Inj.	1000 mL
4	031126	Plabolyte-40	5% Dextrose & 0.3% Potassium Chloride	1000 mL
5	018360	Pladex-5	5% Dextrose	1000 mL
6	003028	Pladexsal	Dextrose Saline	1000 mL
7	003031	Plasaline	Normal Saline	1000 mL
8	018361	Pladex-10	10% Dextrose	1000 mL
9	081059	Pladex-25	25% Dextrose	1000 mL

Further, the Company intends to transfer and sell, the authorizations, product registrations, technical information and, where applicable, inventory relating to the Company's ampoule products namely Dextrose 25%, Potassium Chloride and Meylon for which the Company will take all required steps and approvals at the appropriate time. The Company will accordingly in due course initiate the due diligence process for potential purchasers.

Otsuka Pakistan Ltd.

Head Office : 30-B, Sindhi Muslim Co-operative Housing Society, Karachi-74400, Pakistan. Phones : (+9221) 3452 8651-54 URL www.otsuka.pk
Factory : No. F/4-9, Hub Industrial Trading Estate, Distt. Lasbella, Balochistan, Pakistan. Phones: (+92853) 302363, 303218, 303517, 304395-97



The above disclosures are being made in the interest of transparency and in compliance with the applicable disclosure requirements. The Company will communicate any further material developments to the Pakistan Stock Exchange (PSX) in accordance with applicable laws and regulations.

A disclosure form as required under S.R.O.143(1)/2012 dated December S, 2012, read with Section 96 and Section 131 of the Securities Act, 2015 is also enclosed as **Annexure – A** hereto.

You may please inform the TRE Certificate holders of the Exchange accordingly.

Yours truly,

For and on behalf of Otsuka Pakistan Limited

Company Secretary

CC: Director / HOD
Surveillance, Supervision & Enforcement Department
Securities Exchange Commission of Pakistan,
NIC Building, 63 Jinnah Avenue, Blue Area,
Islamabad.


Otsuka Pakistan Ltd.

Head Office : 30-B, Sindhi Muslim Co-operative Housing Society, Karachi-74400, Pakistan. Phones : (+9221) 3452 8651-54 URL www.otsuka.pk
Factory : No. F/4-9, Hub Industrial Trading Estate, Distt. Lasbella, Balochistan, Pakistan. Phones: (+92853) 302363, 303218, 303517, 304395-97


OTSUKA PAKISTAN LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT SEPTEMBER 30, 2026

		(Unaudited) September 30, 2026	(Audited) June 30, 2026
	Note	-----Rupees in '000-----	
ASSETS			
Non-current assets			
Property, plant and equipment	4	668,503	661,792
Intangible assets		983	1,150
Long-term loans		7,284	6,366
Long-term deposits		1,497	1,497
Deferred tax asset - net		34,631	60,698
		712,898	731,503
Current assets			
Stores and spares		77,772	82,307
Stock-in-trade		1,331,264	1,300,451
Trade debts		168,336	183,452
Loans and advances		67,903	28,976
Trade deposits, short-term prepayments and other receivables		32,203	32,316
Sales tax refundable		47,172	47,172
Advance tax - net		11,670	64,344
Short-term investment		564,610	464,610
Bank balances		67,932	87,144
		2,368,862	2,290,772
Total assets		3,081,760	3,022,275
EQUITY AND LIABILITIES			
Equity			
Share capital	5	121,000	121,000
Revenue reserves		1,177,586	1,039,969
Total equity		1,298,586	1,160,969
Liabilities			
Non-current liabilities			
Lease Liability		5,895	-
Current liabilities			
Short-term loan from a related party	6	971,135	942,700
Trade and other payables		799,483	890,958
Current portion of lease liability		1,351	22,513
Unclaimed dividend		1,908	1,908
Mark-up accrued		3,402	3,227
		1,777,279	1,861,306
Total equity and liabilities		3,081,760	3,022,275
Contingencies and Commitments			
	7		

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.


Chief Executive Officer


Director


Chief Financial Officer







OTSUKA PAKISTAN LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026

	Note	Quarter ended September 30,	
		2026	2025
		----- Rupees in '000 -----	
Revenue from contract with customers	8	1,147,351	1,076,104
Cost of sales		(657,866)	(736,731)
Gross profit		489,485	339,373
Selling and distribution expenses		(179,104)	(158,141)
Administrative and general expenses		(53,890)	(45,743)
		256,491	135,489
Other income		32,042	64,034
		288,533	199,523
Other expenses		(53,998)	(19,658)
Operating profit		234,535	179,864
Finance cost		(4,812)	(2,533)
Profit before levies and taxation		229,723	177,331
Levies		-	(119)
Profit before taxation		229,723	177,212
Taxation		(92,106)	(57,134)
Profit for the period		137,617	120,078
		----- Rupees -----	
Earning per share - basic and diluted		11.37	9.92

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.


Chief Executive Officer


Director


Chief Financial Officer



OTSUKA PAKISTAN LIMITED
CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026

	Quarter ended September 30,	
	2026	2025
	----- Rupees in '000 -----	
Profit for the period	137,617	120,078
Other comprehensive income	-	-
Total comprehensive income for the period	137,617	120,078

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.



Chief Executive Officer




Director



Chief Financial Officer




OTSUKA PAKISTAN LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026


Note	Quarter ended September 30,	
	2026	2025
	----- Rupees in '000 -----	
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before levies and taxation	229,723	177,331
Adjustment for non-cash charges and other items:		
Depreciation & amortisation	34,802	30,283
Unrealized exchange (gain) / loss - net	28,435	(38,500)
Finance cost	4,812	2,533
Operating Cashflow before working capital changes	297,772	171,647
(Increase) / decrease in current assets		
Stores and spares	4,535	(6,422)
Stock-in-trade	(30,813)	(16,434)
Trade debts	15,116	(2,423)
Loans and advances	(38,927)	10,965
Trade deposits, short-term prepayments and other receivables	113	(4,460)
	(49,976)	(18,774)
Increase / (decrease) in current liabilities		
Trade and other payables	(81,945)	10,149
Cash generated from operations	165,851	163,022
Finance cost paid	(4,637)	(2,490)
Taxes paid	(13,365)	(35,531)
(Increase) / decrease in long-term loans	(918)	156
Net cash generated from operations	146,931	125,157
CASH FLOWS FROM INVESTING ACTIVITIES		
Additions to property, plant and equipment	(41,346)	(46,613)
Net cash used in investing activities	(41,346)	(46,613)
CASH FLOWS FROM FINANCING ACTIVITIES		
Lease rentals paid	(24,797)	-
Net cash used in financing activities	(24,797)	-
Net increase in cash and cash equivalents	80,788	78,544
Cash and cash equivalents at the beginning of the period	551,754	378,817
Cash and cash equivalents at the end of the period	632,542	457,361

10

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.



Chief Executive Officer


Director





Chief Financial Officer




OTSUKA PAKISTAN LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
FOR THE QUARTER ENDED SEPTEMBER 30, 2026


	Issued, subscribed and paid-up capital	Revenue reserves			Total
		General reserve	Accumulated losses / (profits)	Sub-total	
		Rupees in '000			
Balance as at June 30, 2025 (audited)	121,000	491,980	82,799	574,779	695,779
Total comprehensive loss for the period ended Sep 30, 2025	-	-	120,078	120,078	120,078
Balance as at Sep 30, 2025	<u>121,000</u>	<u>491,980</u>	<u>202,877</u>	<u>694,857</u>	<u>815,857</u>
Balance as at June 30, 2026 (audited)	121,000	491,980	547,989	1,039,969	1,160,969
Total comprehensive income for the period ended Sep 30, 2026	-	-	137,617	137,617	137,617
Balance as at Sep 30, 2026	<u>121,000</u>	<u>491,980</u>	<u>685,606</u>	<u>1,177,586</u>	<u>1,298,586</u>

The annexed notes 1 to 13 form an integral part of this condensed interim financial information.


Chief Executive Officer


Director




Chief Financial Officer

**DISCLOSURE FORM
IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015**

Name of Company	Otsuka Pakistan Limited
Date of Report	October 28, 2026
Name of Company as specified in the Memorandum	Otsuka Pakistan Limited
Company's Registered Office	30-B, SMCHS, Karachi.
Contact Information	021-34528652

Disclosure of material information by a listed company in terms of Section 96 and 131 of the Securities Act, 2015:

We would like to inform you that the Board of Directors of the Company in its meeting held on October 28, 2026 has approved the reorganizing/ restructuring of its manufacturing facilities located at F/4-9, Hub Industrial Trading Estate, Hub, Lasbella, Balochistan, whereunder the manufacturing of the 1,000 ml products as set out in **Table 1** below, is planned to be transferred from Production Line-II to Production Line-I with effect from January 1, 2027 and the filling machinery installed on Production Line-II, having a carrying amount of approximately Rs. 81 million as at the reporting date, is expected to remain idle as Line-II will be closed following the transfer of production.

Table 1

S. No	Registration No	Drug Name	Generic Substances/ formulation	Pack Size
1	007782	Ringolact	Lactated Ringer's Inj. USP	1000 mL
2	011224	Ringolact-D	5% Dextrose and Lactated Ringer's Inj. USP	1000 mL
3	011225	Plabolyte-M	5% Dextrose and Electrolytes Inj.	1000 mL
4	031126	Plabolyte-40	5% Dextrose & 0.3% Potassium Chloride	1000 mL
5	018360	Pladex-5	5% Dextrose	1000 mL
6	003028	Pladexsal	Dextrose Saline	1000 mL
7	003031	Plasaline	Normal Saline	1000 mL
8	018361	Pladex-10	10% Dextrose	1000 mL
9	081059	Pladex-25	25% Dextrose	1000 mL

Further, the Company intends to transfer and sell, the authorizations, product registrations, technical information and, where applicable, inventory relating to the Company's ampoule products namely Dextrose 25%, Potassium Chloride and Meylon for which the Company will

Otsuka Pakistan Ltd.

Head Office : 30-B, Sindhi Muslim Co-operative Housing Society, Karachi-74400, Pakistan. Phones : (+9221) 3452 8651-54 URL www.otsuka.pk
Factory : No. F/4-9, Hub Industrial Trading Estate, Distt. Lasbella, Balochistan, Pakistan. Phones: (+92853) 302363, 303218, 303517, 304395-97




take all required steps and approvals at the appropriate time. The Company will accordingly in due course initiate the due diligence process for potential purchasers.

Pursuant to the requirements of the Securities Act, 2015, the Company has duly caused this form/statement to be signed on its behalf by the undersigned hereunto duly authorized.

For and on behalf of
Otsuka Pakistan Limited

Company Secretary



Otsuka Pakistan Ltd.

Head Office : 30-B, Sindhi Muslim Co-operative Housing Society, Karachi-74400, Pakistan. Phones : (+9221) 3452 8651-54 URL www.otsuka.pk
Factory : No. F/4-9, Hub Industrial Trading Estate, Distt. Lasbella, Balochistan, Pakistan. Phones: (+92853) 302363, 303218, 303517, 304395-97